生物科技行业面临挑战，10X Genomics Inc (TXG)股价跌至52周新低，触及11.89美元。根据 InvestingPro 数据显示，技术指标表明该股票已处于超卖区域，公司保持着4.9的健康流动比率。这一最新价格水平凸显了公司股价的急剧下跌，过去一年累计下跌75.65%。投资者正在应对行业整体压力和公司特定不利因素的双重影响，导致持续抛售，最终使公司股价创下新低。这个52周低点清晰地 ...

Investing.com -- 实验室工具设备行业的公司股票，包括Bruker、Illumina、Quanterix、Bio-Techne、10X Genomics和Qiagen，在盘前交易中出现下跌。这一下跌趋势是在美国国立卫生研究院（NIH）宣布计划通过降低 ...

技术优势：为何DEFND-seq是游戏规则改变者？ “一站式”分析平台：无需改造设备，直接兼容10x Genomics商业化系统，全球实验室可快速部署。 冷冻 ...

Biotechnology company 10x Genomics and Harvard University reached a Feb. 6 settlement in a patent lawsuit that they jointly ...

Biotech company 10x Genomics (NASDAQ:TXG) will be reporting earnings tomorrow after market hours. Here’s what to look for. 10x Genomics missed analysts’ revenue expectations by 5% last quarter ...

10x Genomics Price Performance Shares of TXG opened at $12.31 on Tuesday. The firm has a market cap of $1.49 billion, a PE ratio of -8.05 and a beta of 1.85. The stock’s fifty day moving average ...

Morgan Stanley analyst Tejas Savant maintained a Buy rating on 10x Genomics (TXG – Research Report) today and set a price target of $26.00. The ...

Genomics reported a Q4 EPS loss of $(0.40), missing estimates, while revenue declined 10% year over year. Analysts lowered ...

Genomics company 10x and Harvard University have agreed to resolve a patent lawsuit against 10x's rival Vizgen four days into a scheduled two-week trial, according to a Thursday filing in Delaware ...

Leerink Partners lowered 10x Genomics from an “outperform” rating to a “market perform” rating and cut their price target for the stock from $25.00 to $12.00 in a research report on Thursday.

Barclays lowered the firm’s price target on 10x Genomics (TXG) to $15 from $18 and keeps an Overweight rating on the shares.Maximize Your ...

Biotech company 10x Genomics (NASDAQ:TXG) reported Q4 CY2024 results beating Wall Street’s revenue expectations , but sales fell by 10.3% year on year to $165 million. On the other hand, ...